Supplement encyclopedia

Resveratrol

Resveratrol is a plant compound found in some foods and used in dietary supplements.

Double-check conclusions and examine the sources before choosing a supplement.

Main conclusion

What it may offer

  • In postmenopausal women, resveratrol may slightly improve performance on mental tasks when taken at 75 mg twice daily for one year. A review of individual memory and processing speed tests found no convincing advantage.
  • In the RESHAW program, postmenopausal women reported better pain scores than with placebo; each treatment period lasted one year. Results for overall well-being and menopausal symptoms differ between analyses.
  • In healthy women aged 40 and over, capsules alone showed no convincing advantage in reducing wrinkles over eight weeks. The improvement in this study concerned the combination of capsules and cream.
  • In older men, 250 mg of resveratrol daily for eight weeks attenuated the increase in the ability to use oxygen during exercise compared with placebo. The result does not support choosing this supplement to enhance training effects.
  • In a small experiment, pain after a series of jumps was lower, and some jumping and cycling test measures at 72 hours were better than with placebo. No clear difference in muscle soreness was found after a marathon.
  • After one type of resistance exercise in a small study, pain was lower after one day, but the supplement did not prevent loss of strength. Another short cycling test found no clear performance advantage.
  • A review of adults with varying health conditions found no convincing reduction in weight, fat mass, or waist or hip measurements. These findings do not support choosing the supplement for weight loss.

[1] [2] [3] [4] [5] [6] [7]

What was studied

  • The RESHAW program studied memory, mental task performance, pain and well-being in postmenopausal women: the first phase lasted one year, and the crossover study had two one-year periods.
  • Wrinkles were studied over eight weeks in healthy women aged 40 and over, and the response to training over eight weeks in older men.
  • Muscle soreness, strength and performance after exercise were studied in athletes and untrained adults; supplementation in individual studies lasted from four to ten days.
  • Weight and body composition were studied in different groups of adults, including people with illnesses and healthy older adults. Preparations, doses and durations varied across the review; the total number of trials in the review cannot be presented as the number of studies for each outcome.

[1] [2] [3] [4] [5] [6] [7]

Forms considered

  • RESHAW studied synthetic trans-resveratrol at 75 mg twice daily. When choosing a supplement, it is important to distinguish this form from multi-ingredient formulations.
  • The Canadian monograph covers plant-derived and synthetic oral trans-resveratrol preparations. Foods and food-like forms are excluded.

[1] [2]

How to obtain it from food

  • Food sources of resveratrol include grapes and grape juice, blueberries, bilberries, cranberries and lingonberries, peanuts and peanut butter, as well as cocoa and some types of chocolate.
  • The content and forms of resveratrol vary between foods. A serving of food cannot be equated with a studied dose of purified trans-resveratrol in a capsule.

[1] [2] [3] [4] [5] [6]

Effects and studied questions

How to read the certainty scale 1–4

Certainty is rated separately for each outcome. 1 is very low, 2 is low, 3 is moderate and 4 is high.

Goal or questionResultConfidenceStudiesPopulation studiedKey sources
Overall mental task performanceIn postmenopausal women in the RESHAW study, the authors reported a small effect on the overall cognitive score after 12 months of supplementation; group values and the authors’ between-group estimate are presented separately.Overall score (mean ± SEM) at baseline −0.09±0.05 versus −0.08±0.07; at 12 months +0.18±0.05 versus +0.17±0.06. These are group scores, not a calculated between-group difference. The authors reported between-group p<0.001, d=0.18.
2/4 LowA single research project and a specific group of postmenopausal women limit generalizability. The group scores and the between-group result reported by the authors require cautious interpretation.
11 trialSustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗Postmenopausal women; 146 randomized, 129 completed the first year
  1. Sustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗
Wrinkles: capsulesIn an eight-week study of healthy women aged 40 and over, between-group significance of the change in the total wrinkle score was not indicated in the table for the oral resveratrol-only group.Change −0.44±0.52 versus −0.31±0.32; between-group significance in the table was indicated only for the combination of active capsules and cream.
2/4 LowOne small study group cannot rule out a small effect. Statistical significance in the table is indicated for the combination of capsules and cream, not for capsules alone.
11 trialTrans-resveratrol reduces visible signs of skin ageing in healthy adult females over 40: an 8-week randomized placebo-controlled trial ↗Healthy women aged 40 and over; 61 participants in the comparison: 32 in the oral group and 29 in the double-placebo group
  1. Trans-resveratrol reduces visible signs of skin ageing in healthy adult females over 40: an 8-week randomized placebo-controlled trial ↗
Information processing speedIn the study of postmenopausal women, the information processing speed measure after 12 months: At baseline −0.08 ± 0.10 versus 0.05 ± 0.09, at 12 months 0.24 ± 0.09 versus 0.23 ± 0.10; z-scores, mean ± SEM; values as in the table. The authors reported a statistically significant between-group difference in change.At baseline −0.08 ± 0.10 versus 0.05 ± 0.09, at 12 months 0.24 ± 0.09 * versus 0.23 ± 0.10; z-scores, mean ± SEM; values as in the table.
1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified.
11 trialSustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12
  1. Sustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗

The study count refers to the cited source. Reviews with overlapping trials and outcomes from one study are not added together.

Daily intake requirements and upper limits

Intake and studied regimens
ContextDetails
Intake and studied regimensThe Canadian monograph for licensed oral preparations for adults specifies no more than 1 g/day; consultation is required for more than 500 mg/day for longer than three months. These are conditions for a category of products, not a universal upper limit.

RESVERATROL — Natural Health Product Monograph ↗

Forms

Trans-resveratrol occurs in plant-derived or synthetic preparations; food matrices, isomers and formulations differ. RESHAW used synthetic trans-resveratrol of over 98% purity; conjugated metabolites predominated in plasma after intake.

Guidance for each goal

Overall mental task performance2/4 LowRead moreCollapse
Confidence
2/4 LowA single research project and a specific group of postmenopausal women limit generalizability. The group scores and the between-group result reported by the authors require cautious interpretation.

In postmenopausal women in the RESHAW study, the authors reported a small effect on the overall cognitive score after 12 months of supplementation; group values and the authors’ between-group estimate are presented separately.

Study findings. In postmenopausal women in the RESHAW study, the authors reported a small effect on the overall cognitive score after 12 months of supplementation; group values and the authors’ between-group estimate are presented separately.

Studied regimen75 mg twice dailysynthetic trans-resveratrol >98%
Duration and population12 months; first phase of the crossover studyPostmenopausal women; 146 randomized, 129 completed the first year

Comparison with placebo

Wrinkles: capsules2/4 LowRead moreCollapse
Confidence
2/4 LowOne small study group cannot rule out a small effect. Statistical significance in the table is indicated for the combination of capsules and cream, not for capsules alone.

In an eight-week study of healthy women aged 40 and over, between-group significance of the change in the total wrinkle score was not indicated in the table for the oral resveratrol-only group.

Study findings. In an eight-week study of healthy women aged 40 and over, between-group significance of the change in the total wrinkle score was not indicated in the table for the oral resveratrol-only group.

Studied regimen75 mg twice daily plus placebo creamtrans-resveratrol capsules
Duration and population8 weeksHealthy women aged 40 and over; 61 participants in the comparison: 32 in the oral group and 29 in the double-placebo group

Comparison with double placebo

Information processing speed1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified.

In the study of postmenopausal women, the information processing speed measure after 12 months: At baseline −0.08 ± 0.10 versus 0.05 ± 0.09, at 12 months 0.24 ± 0.09 versus 0.23 ± 0.10; z-scores, mean ± SEM; values as in the table. The authors reported a statistically significant between-group difference in change.

Study findings. In the study of postmenopausal women, the information processing speed measure after 12 months: At baseline −0.08 ± 0.10 versus 0.05 ± 0.09, at 12 months 0.24 ± 0.09 versus 0.23 ± 0.10; z-scores, mean ± SEM; values as in the table. The authors reported a statistically significant between-group difference in change.

Studied regimen75 mg twice dailysynthetic trans-resveratrol >98%
Duration and population12 months; first phase of the crossover studyPostmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12

Comparison with placebo

PCT picture comparison speed test1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified.

In the study of postmenopausal women, the PCT picture comparison speed test measure after 12 months: At baseline −0.13 ± 0.13 versus 0.08 ± 0.12, at 12 months 0.32 ± 0.11 versus 0.15 ± 0.13; z-scores, mean ± SEM; values as in the table. The authors reported a statistically significant between-group difference in change.

Study findings. In the study of postmenopausal women, the PCT picture comparison speed test measure after 12 months: At baseline −0.13 ± 0.13 versus 0.08 ± 0.12, at 12 months 0.32 ± 0.11 versus 0.15 ± 0.13; z-scores, mean ± SEM; values as in the table. The authors reported a statistically significant between-group difference in change.

Studied regimen75 mg twice dailysynthetic trans-resveratrol >98%
Duration and population12 months; first phase of the crossover studyPostmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12

Comparison with placebo

TMT A sequential connecting-the-dots test1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified.

In the study of postmenopausal women, the TMT A sequential connecting-the-dots test measure after 12 months: At baseline −0.02 ± 0.11 versus 0.02 ± 0.13, at 12 months 0.16 ± 0.11 versus 0.31 ± 0.11; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.

Study findings. In the study of postmenopausal women, the TMT A sequential connecting-the-dots test measure after 12 months: At baseline −0.02 ± 0.11 versus 0.02 ± 0.13, at 12 months 0.16 ± 0.11 versus 0.31 ± 0.11; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.

Studied regimen75 mg twice dailysynthetic trans-resveratrol >98%
Duration and population12 months; first phase of the crossover studyPostmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12

Comparison with placebo

Language abilities1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified.

In the study of postmenopausal women, the language abilities measure after 12 months: At baseline 0.03 ± 0.11 versus −0.03 ± 0.10, at 12 months 0.09 ± 0.11 versus 0.04 ± 0.11; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.

Study findings. In the study of postmenopausal women, the language abilities measure after 12 months: At baseline 0.03 ± 0.11 versus −0.03 ± 0.10, at 12 months 0.09 ± 0.11 versus 0.04 ± 0.11; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.

Studied regimen75 mg twice dailysynthetic trans-resveratrol >98%
Duration and population12 months; first phase of the crossover studyPostmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12

Comparison with placebo

PVT vocabulary test1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified.

In the study of postmenopausal women, the PVT vocabulary test measure after 12 months: At baseline 0.09 ± 0.12 versus −0.09 ± 0.12, at 12 months 0.20 ± 0.13 versus 0.05 ± 0.13; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.

Study findings. In the study of postmenopausal women, the PVT vocabulary test measure after 12 months: At baseline 0.09 ± 0.12 versus −0.09 ± 0.12, at 12 months 0.20 ± 0.13 versus 0.05 ± 0.13; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.

Studied regimen75 mg twice dailysynthetic trans-resveratrol >98%
Duration and population12 months; first phase of the crossover studyPostmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12

Comparison with placebo

ORR oral reading recognition1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified.

In the study of postmenopausal women, the ORR oral reading recognition measure after 12 months: At baseline −0.02 ± 0.12 versus 0.02 ± 0.12, at 12 months −0.02 ± 0.11 versus 0.04 ± 0.10; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.

Study findings. In the study of postmenopausal women, the ORR oral reading recognition measure after 12 months: At baseline −0.02 ± 0.12 versus 0.02 ± 0.12, at 12 months −0.02 ± 0.11 versus 0.04 ± 0.10; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.

Studied regimen75 mg twice dailysynthetic trans-resveratrol >98%
Duration and population12 months; first phase of the crossover studyPostmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12

Comparison with placebo

Episodic memory1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified.

In the study of postmenopausal women, the episodic memory measure after 12 months: At baseline −0.47 ± 0.10 versus −0.49 ± 0.09, at 12 months −0.19 ± 0.11 versus −0.27 ± 0.10; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.

Study findings. In the study of postmenopausal women, the episodic memory measure after 12 months: At baseline −0.47 ± 0.10 versus −0.49 ± 0.09, at 12 months −0.19 ± 0.11 versus −0.27 ± 0.10; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.

Studied regimen75 mg twice dailysynthetic trans-resveratrol >98%
Duration and population12 months; first phase of the crossover studyPostmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12

Comparison with placebo

PSM picture sequence memory test1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified.

In the study of postmenopausal women, the PSM picture sequence memory test measure after 12 months: At baseline −0.47 ± 0.10 versus −0.49 ± 0.09, at 12 months −0.19 ± 0.11 versus −0.27 ± 0.10; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.

Study findings. In the study of postmenopausal women, the PSM picture sequence memory test measure after 12 months: At baseline −0.47 ± 0.10 versus −0.49 ± 0.09, at 12 months −0.19 ± 0.11 versus −0.27 ± 0.10; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.

Studied regimen75 mg twice dailysynthetic trans-resveratrol >98%
Duration and population12 months; first phase of the crossover studyPostmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12

Comparison with placebo

Verbal memory1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified.

In the study of postmenopausal women, the verbal memory measure after 12 months: At baseline −0.001 ± 0.1 versus 0.001 ± 0.1, at 12 months 0.12 ± 0.10 versus 0.17 ± 0.12; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.

Study findings. In the study of postmenopausal women, the verbal memory measure after 12 months: At baseline −0.001 ± 0.1 versus 0.001 ± 0.1, at 12 months 0.12 ± 0.10 versus 0.17 ± 0.12; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.

Studied regimen75 mg twice dailysynthetic trans-resveratrol >98%
Duration and population12 months; first phase of the crossover studyPostmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12

Comparison with placebo

RAVLT immediate word recall1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified.

In the study of postmenopausal women, the RAVLT immediate word recall measure after 12 months: At baseline −0.02 ± 0.07 versus 0.02 ± 0.07, at 12 months 0.07 ± 0.06 versus 0.07 ± 0.06; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.

Study findings. In the study of postmenopausal women, the RAVLT immediate word recall measure after 12 months: At baseline −0.02 ± 0.07 versus 0.02 ± 0.07, at 12 months 0.07 ± 0.06 versus 0.07 ± 0.06; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.

Studied regimen75 mg twice dailysynthetic trans-resveratrol >98%
Duration and population12 months; first phase of the crossover studyPostmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12

Comparison with placebo

RAVLT delayed word recall1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified.

In the study of postmenopausal women, the RAVLT delayed word recall measure after 12 months: At baseline 0.02 ± 0.15 versus −0.02 ± 0.15, at 12 months 0.17 ± 0.16 versus 0.28 ± 0.19; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.

Study findings. In the study of postmenopausal women, the RAVLT delayed word recall measure after 12 months: At baseline 0.02 ± 0.15 versus −0.02 ± 0.15, at 12 months 0.17 ± 0.16 versus 0.28 ± 0.19; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.

Studied regimen75 mg twice dailysynthetic trans-resveratrol >98%
Duration and population12 months; first phase of the crossover studyPostmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12

Comparison with placebo

Working memory1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified.

In the study of postmenopausal women, the working memory measure after 12 months: At baseline −0.04 ± 0.10 versus 0.04 ± 0.10, at 12 months 0.05 ± 0.09 versus 0.06 ± 0.09; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.

Study findings. In the study of postmenopausal women, the working memory measure after 12 months: At baseline −0.04 ± 0.10 versus 0.04 ± 0.10, at 12 months 0.05 ± 0.09 versus 0.06 ± 0.09; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.

Studied regimen75 mg twice dailysynthetic trans-resveratrol >98%
Duration and population12 months; first phase of the crossover studyPostmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12

Comparison with placebo

LSWM working memory test1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified.

In the study of postmenopausal women, the LSWM working memory test measure after 12 months: At baseline −0.11 ± 0.12 versus 0.11 ± 0.11, at 12 months −0.03 ± 0.13 versus 0.08 ± 0.14; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.

Study findings. In the study of postmenopausal women, the LSWM working memory test measure after 12 months: At baseline −0.11 ± 0.12 versus 0.11 ± 0.11, at 12 months −0.03 ± 0.13 versus 0.08 ± 0.14; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.

Studied regimen75 mg twice dailysynthetic trans-resveratrol >98%
Duration and population12 months; first phase of the crossover studyPostmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12

Comparison with placebo

FSS spatial memory test1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified.

In the study of postmenopausal women, the FSS spatial memory test measure after 12 months: At baseline 0.04 ± 0.11 versus −0.04 ± 0.12, at 12 months 0.12 ± 0.10 versus 0.06 ± 0.12; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.

Study findings. In the study of postmenopausal women, the FSS spatial memory test measure after 12 months: At baseline 0.04 ± 0.11 versus −0.04 ± 0.12, at 12 months 0.12 ± 0.10 versus 0.06 ± 0.12; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.

Studied regimen75 mg twice dailysynthetic trans-resveratrol >98%
Duration and population12 months; first phase of the crossover studyPostmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12

Comparison with placebo

Flexibility in switching between mental tasks1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified.

In the study of postmenopausal women, the cognitive flexibility measure after 12 months: At baseline 0.03 ± 0.08 versus −0.03 ± 0.12, at 12 months 0.82 ± 0.07 versus 0.78 ± 0.08; z-scores, mean ± SEM; values as in the table. The authors reported a statistically significant between-group difference in change.

Study findings. In the study of postmenopausal women, the cognitive flexibility measure after 12 months: At baseline 0.03 ± 0.08 versus −0.03 ± 0.12, at 12 months 0.82 ± 0.07 versus 0.78 ± 0.08; z-scores, mean ± SEM; values as in the table. The authors reported a statistically significant between-group difference in change.

Studied regimen75 mg twice dailysynthetic trans-resveratrol >98%
Duration and population12 months; first phase of the crossover studyPostmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12

Comparison with placebo

DCCS rule-switching test1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified.

In the study of postmenopausal women, the DCCS rule-switching test measure after 12 months: At baseline 0.05 ± 0.09 versus −0.05 ± 0.14, at 12 months 0.23 ± 0.10 versus 0.10 ± 0.13; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.

Study findings. In the study of postmenopausal women, the DCCS rule-switching test measure after 12 months: At baseline 0.05 ± 0.09 versus −0.05 ± 0.14, at 12 months 0.23 ± 0.10 versus 0.10 ± 0.13; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.

Studied regimen75 mg twice dailysynthetic trans-resveratrol >98%
Duration and population12 months; first phase of the crossover studyPostmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12

Comparison with placebo

FICA attention and inhibition test1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified.

In the study of postmenopausal women, the FICA attention and inhibition test measure after 12 months: At baseline 0.08 ± 0.11 versus −0.08 ± 0.12, at 12 months 0.26 ± 0.12 versus 0.22 ± 0.11; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.

Study findings. In the study of postmenopausal women, the FICA attention and inhibition test measure after 12 months: At baseline 0.08 ± 0.11 versus −0.08 ± 0.12, at 12 months 0.26 ± 0.12 versus 0.22 ± 0.11; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.

Studied regimen75 mg twice dailysynthetic trans-resveratrol >98%
Duration and population12 months; first phase of the crossover studyPostmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12

Comparison with placebo

Sequential connecting of dots in the TMT1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified.

In the study of postmenopausal women, the TMT test score measure after 12 months: At baseline −0.02 ± 0.19 versus 0.02 ± 0.21, at 12 months 1.97 ± 0.11 versus 2.01 ± 0.10; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.

Study findings. In the study of postmenopausal women, the TMT test score measure after 12 months: At baseline −0.02 ± 0.19 versus 0.02 ± 0.21, at 12 months 1.97 ± 0.11 versus 2.01 ± 0.10; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.

Studied regimen75 mg twice dailysynthetic trans-resveratrol >98%
Duration and population12 months; first phase of the crossover studyPostmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12

Comparison with placebo

Change in VO₂max2/4 LowRead moreCollapse
Confidence
2/4 LowOne small study with a specific training program in older men limits generalizability. The between-group result concerns change in VO₂max, not all measures of fitness.

In 27 older men following the same training program, the increase in VO₂max was smaller with 250 mg of trans-resveratrol daily for 8 weeks than with placebo: VO₂max increase: 308±46 mL/min with resveratrol versus 444±38 mL/min with placebo (mean ± SEM), p<0.05; the increase in the placebo group was 45% greater.

Study findings. In 27 older men following the same training program, the increase in VO₂max was smaller with 250 mg of trans-resveratrol daily for 8 weeks than with placebo: VO₂max increase: 308±46 mL/min with resveratrol versus 444±38 mL/min with placebo (mean ± SEM), p<0.05; the increase in the placebo group was 45% greater.

Studied regimen250 mg/dayoral trans-resveratrol
Duration and population8 weeks27 older men, 14/13

Comparison with placebo; both groups trained

Soreness after a marathon1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowOne small study and its specific participants and exercise loads limit generalizability. The review reports direction and significance, but gives no numerical between-group effect for this outcome.

According to a systematic review, in the Laupheimer 2014 study: the review reports no significant between-group difference in soreness after a marathon.

Study findings. According to a systematic review, in the Laupheimer 2014 study: the review reports no significant between-group difference in soreness after a marathon.

Studied regimen600 mg/dayresveratrol preparation
Duration and population7 days before the marathon7 male athletes, 3/4

Comparison with placebo

Muscle pain and recovery after jumping1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowOne small study and its specific participants and exercise loads limit generalizability. The review reports direction and significance, but gives no numerical between-group effect for this outcome.

The review reports that in Huang 2021 muscle pain and recovery of performance after jumping exercise were better in the resveratrol group; numerical between-group estimates were not provided.

Study findings. The review reports that in Huang 2021 muscle pain and recovery of performance after jumping exercise were better in the resveratrol group; numerical between-group estimates were not provided.

Studied regimen500 or 1000 mg/daytrans-resveratrol
Duration and population10 days and 72 hours of observation after exercise36 men without athletic training, 12 per group

Comparison with 1000 mg/day methylcellulose

High-intensity cycling test performance1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowOne small study and its specific participants and exercise loads limit generalizability. The review reports direction and significance, but gives no numerical between-group effect for this outcome.

According to a systematic review, in the Tsao 2021 study: the review reports no significant improvement in high-intensity cycling performance.

Study findings. According to a systematic review, in the Tsao 2021 study: the review reports no significant improvement in high-intensity cycling performance.

Studied regimen480 mg/dayresveratrol capsules
Duration and population4 days, 7-day washout8 physically active men, crossover comparison

Comparison with placebo

Pain and strength loss after eccentric exercise1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowOne small study and its specific participants and exercise loads limit generalizability. The review reports direction and significance, but gives no numerical between-group effect for this outcome.

According to a systematic review, in the Kristoffersen 2022 study: the review reports reduced pain at 24 hours but no prevention of strength loss.

Study findings. According to a systematic review, in the Kristoffersen 2022 study: the review reports reduced pain at 24 hours but no prevention of strength loss.

Studied regimen500 mg/dayresveratrol preparation
Duration and population5 days, including 3 days before exercise18 untrained adults, 9/9

Comparison with calcium capsules 400 mg/day, as stated in the review

Overall mental task performance: crossover comparison1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The number analyzed for this outcome is not separately disclosed in the available abstract; full text is available by subscription.

In the RESHAW crossover study of postmenopausal women, for the overall cognitive score: Cohen d=0.170, p=0.005; the authors reported a 33% relative change in the composite score.

Study findings. In the RESHAW crossover study of postmenopausal women, for the overall cognitive score: Cohen d=0.170, p=0.005; the authors reported a 33% relative change in the composite score.

Studied regimen75 mg twice dailytrans-resveratrol
Duration and population12 months per period, 24 months total125 postmenopausal women in the RESHAW crossover study; the number analyzed for the individual outcome is not established

Comparison with placebo; crossover comparison

Composite pain score1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The number analyzed for this outcome is not separately disclosed in the available abstract; full text is available by subscription.

In the RESHAW crossover study of postmenopausal women, for the composite pain score: the authors reported improvement in the composite pain score, p<0.001; a quantitative between-group difference was not provided in the available abstract.

Study findings. In the RESHAW crossover study of postmenopausal women, for the composite pain score: the authors reported improvement in the composite pain score, p<0.001; a quantitative between-group difference was not provided in the available abstract.

Studied regimen75 mg twice dailytrans-resveratrol
Duration and population12 months per period125 postmenopausal women in the RESHAW crossover study; the number analyzed for the individual outcome is not established

Comparison with placebo

Somatic symptoms1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The number analyzed for this outcome is not separately disclosed in the available abstract; full text is available by subscription.

In the RESHAW crossover study of postmenopausal women, for somatic symptoms: the authors reported improvement in somatic symptoms, p=0.024; a quantitative difference was not provided in the abstract.

Study findings. In the RESHAW crossover study of postmenopausal women, for somatic symptoms: the authors reported improvement in somatic symptoms, p=0.024; a quantitative difference was not provided in the abstract.

Studied regimen75 mg twice dailytrans-resveratrol
Duration and population12 months per period, 24 months total125 postmenopausal women in the RESHAW crossover study; the number analyzed for the individual outcome is not established

Comparison with placebo; crossover comparison

Overall well-being1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The number analyzed for this outcome is not separately disclosed in the available abstract; full text is available by subscription.

In the RESHAW crossover study of postmenopausal women, for overall well-being: the authors reported improvement in overall well-being, p=0.010; a quantitative difference was not provided in the abstract.

Study findings. In the RESHAW crossover study of postmenopausal women, for overall well-being: the authors reported improvement in overall well-being, p=0.010; a quantitative difference was not provided in the abstract.

Studied regimen75 mg twice dailytrans-resveratrol
Duration and population12 months per period, 24 months total125 postmenopausal women in the RESHAW crossover study; the number analyzed for the individual outcome is not established

Comparison with placebo; crossover comparison

Information processing speed (PCT)1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowThe review combines interim and crossover publications from the same RESHAW program, so the rows are not independent participants or trials. The number of unique people and the number of participants in the analysis of this outcome are not established, and the confidence interval includes no effect.

A review of postmenopausal women found no statistically significant difference in PCT: WMD +0.088 (95% CI −0.099…+0.274), p=0.358 The pooled RESHAW publications belong to one program.

Study findings. A review of postmenopausal women found no statistically significant difference in PCT: WMD +0.088 (95% CI −0.099…+0.274), p=0.358 The pooled RESHAW publications belong to one program.

Studied regimen75 mg twice dailytrans-resveratrol
Duration and population12 months per period in RESHAW; first-year and crossover comparison reportsPostmenopausal women in the studies in the review

Comparison with placebo

TMT A task performance1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowThe review combines interim and crossover publications from the same RESHAW program, so the rows are not independent participants or trials. The number of unique people and the number of participants in the analysis of this outcome are not established, and the confidence interval includes no effect.

A review of postmenopausal women found no statistically significant difference in TMT A: WMD +0.026 (95% CI −0.147…+0.199), p=0.769 The pooled RESHAW publications belong to one program.

Study findings. A review of postmenopausal women found no statistically significant difference in TMT A: WMD +0.026 (95% CI −0.147…+0.199), p=0.769 The pooled RESHAW publications belong to one program.

Studied regimen75 mg twice dailyresveratrol; trans-resveratrol in RESHAW, form not specified in the Evans report
Duration and population14 weeks in the pilot study and 12 months per period in RESHAWPostmenopausal women in the studies in the review

Comparison with placebo

Immediate word recall (RAVLT)1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowThe review combines interim and crossover publications from the same RESHAW program, so the rows are not independent participants or trials. The number of unique people and the number of participants in the analysis of this outcome are not established, and the confidence interval includes no effect.

A review of postmenopausal women found no statistically significant difference in RAVLT immediate recall: WMD +0.004 (95% CI −0.102…+0.110), p=0.939 The pooled RESHAW publications belong to one program.

Study findings. A review of postmenopausal women found no statistically significant difference in RAVLT immediate recall: WMD +0.004 (95% CI −0.102…+0.110), p=0.939 The pooled RESHAW publications belong to one program.

Studied regimen75 mg twice dailyresveratrol; trans-resveratrol in RESHAW, form not specified in the Evans report
Duration and population14 weeks in the pilot study and 12 months per period in RESHAWPostmenopausal women in the studies in the review

Comparison with placebo

Delayed word recall (RAVLT)1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowThe review combines interim and crossover publications from the same RESHAW program, so the rows are not independent participants or trials. The number of unique people and the number of participants in the analysis of this outcome are not established, and the confidence interval includes no effect.

A review of postmenopausal women found no statistically significant difference in RAVLT delayed recall: WMD +0.064 (95% CI −0.550…+0.678), p=0.838 The pooled RESHAW publications belong to one program.

Study findings. A review of postmenopausal women found no statistically significant difference in RAVLT delayed recall: WMD +0.064 (95% CI −0.550…+0.678), p=0.838 The pooled RESHAW publications belong to one program.

Studied regimen75 mg twice dailyresveratrol; trans-resveratrol in RESHAW, form not specified in the Evans report
Duration and population14 weeks in the pilot study and 12 months per period in RESHAWPostmenopausal women in the studies in the review

Comparison with placebo

Working memory (LSWM)1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowThe review combines interim and crossover publications from the same RESHAW program, so the rows are not independent participants or trials. The number of unique people and the number of participants in the analysis of this outcome are not established, and the confidence interval includes no effect.

A review of postmenopausal women found no statistically significant difference in LSWM working memory: WMD −0.066 (95% CI −0.293…+0.161), p=0.567 The pooled RESHAW publications belong to one program.

Study findings. A review of postmenopausal women found no statistically significant difference in LSWM working memory: WMD −0.066 (95% CI −0.293…+0.161), p=0.567 The pooled RESHAW publications belong to one program.

Studied regimen75 mg twice dailytrans-resveratrol
Duration and population12 months per period in RESHAW; first-year and crossover comparison reportsPostmenopausal women in the studies in the review

Comparison with placebo

Spatial memory (FSS)1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowThe review combines interim and crossover publications from the same RESHAW program, so the rows are not independent participants or trials. The number of unique people and the number of participants in the analysis of this outcome are not established, and the confidence interval includes no effect.

A review of postmenopausal women found no statistically significant difference in FSS working memory: WMD +0.180 (95% CI −0.021…+0.380), p=0.079 The pooled RESHAW publications belong to one program.

Study findings. A review of postmenopausal women found no statistically significant difference in FSS working memory: WMD +0.180 (95% CI −0.021…+0.380), p=0.079 The pooled RESHAW publications belong to one program.

Studied regimen75 mg twice dailytrans-resveratrol
Duration and population12 months per period in RESHAW; first-year and crossover comparison reportsPostmenopausal women in the studies in the review

Comparison with placebo

Body weight2/4 LowRead moreCollapse
Confidence
2/4 LowFor body weight, the confidence interval includes no difference; the exact number of unique participants in this analysis is not established. The review combined different groups and doses; selection of individual study arms and independence of some publications are not entirely clear.

A review of adults with various conditions, including cardiometabolic disorders, reported for body weight: SMD +0.041 (95% CI −0.136…+0.217). Study conditions and source limitations are considered separately.

Study findings. A review of adults with various conditions, including cardiometabolic disorders, reported for body weight: SMD +0.041 (95% CI −0.136…+0.217). Study conditions and source limitations are considered separately.

Studied regimen40–3000 mg/day, specific alternatives are given in the protocolsoral resveratrol preparations; in some trials the graph does not specify whether the single-ingredient or combination arm was selected
Duration and population45 days, 8 weeks, 12 weeks, 90 days, 3 months, 6 months, 5 weeks, 16 weeks, 26 weeksHeterogeneous groups of adults; included conditions and groups: type 2 diabetes; non-alcoholic fatty liver disease; metabolic syndrome; obesity; in some studies, no other diseases; healthy older adults.

Comparison with control

Fat mass2/4 LowRead moreCollapse
Confidence
2/4 LowFor fat mass, the confidence interval includes no difference; the exact number of unique participants in this analysis is not established. The review combined different groups and doses; selection of individual study arms and independence of some publications are not entirely clear.

A review of adults with various conditions, including cardiometabolic disorders, reported for fat mass: SMD −0.202 (95% CI −0.410…+0.007). Study conditions and source limitations are considered separately.

Study findings. A review of adults with various conditions, including cardiometabolic disorders, reported for fat mass: SMD −0.202 (95% CI −0.410…+0.007). Study conditions and source limitations are considered separately.

Studied regimen40–1500 mg/day, specific alternatives are given in the protocolsoral resveratrol preparations; in some trials the graph does not specify whether the single-ingredient or combination arm was selected
Duration and population90 days, 6 months, 16 weeks, 26 weeksHeterogeneous groups of adults; included conditions and groups: metabolic syndrome; obesity; in some studies, no other diseases; type 2 diabetes; healthy older adults.

Comparison with control

BMI3/4 ModerateRead moreCollapse
Confidence
3/4 ModerateFor BMI, the confidence interval includes no difference; the exact number of unique participants in this analysis is not established. For some rows in the review, it is unclear which arms were selected and whether individual publications refer to the same participants.

A review of adults with various conditions, including cardiometabolic disorders, reported for BMI: SMD −0.075 (95% CI −0.193…+0.043). Study conditions and source limitations are considered separately.

Study findings. A review of adults with various conditions, including cardiometabolic disorders, reported for BMI: SMD −0.075 (95% CI −0.193…+0.043). Study conditions and source limitations are considered separately.

Studied regimen40–3000 mg/day, specific alternatives are given in the protocolsoral resveratrol preparations; in some trials the graph does not specify whether the single-ingredient or combination arm was selected
Duration and population45 days, 8 weeks, 12 weeks, 90 days, 3 months, 4 weeks, 6 months, 16 weeks, 26 weeks, 2 monthsHeterogeneous groups of adults; included conditions and groups: type 2 diabetes; non-alcoholic fatty liver disease; metabolic syndrome; overweight or moderate obesity; obesity; in some studies, no other diseases; healthy older adults; dyslipidemia; ulcerative colitis.

Comparison with control

Hip circumference3/4 ModerateRead moreCollapse
Confidence
3/4 ModerateFor hip circumference, the confidence interval includes no difference; the exact number of unique participants in this analysis is not established. The review does not make clear which arms were included in individual estimates; both groups compared in one study followed a Mediterranean diet.

A review of adults with various conditions, including cardiometabolic disorders, reported for hip circumference: SMD −0.037 (95% CI −0.270…+0.197). Study conditions and source limitations are considered separately.

Study findings. A review of adults with various conditions, including cardiometabolic disorders, reported for hip circumference: SMD −0.037 (95% CI −0.270…+0.197). Study conditions and source limitations are considered separately.

Studied regimen500–800 mg/day, specific alternatives are given in the protocolsoral resveratrol preparations; composition and purity of individual preparations were not specified
Duration and population12 weeks, 3 months, 8 weeksHeterogeneous groups of adults; included conditions and groups: non-alcoholic fatty liver disease; type 2 diabetes; ulcerative colitis.

Comparison with control

Waist circumference3/4 ModerateRead moreCollapse
Confidence
3/4 ModerateFor waist circumference, the confidence interval includes no difference; the exact number of unique participants in this analysis is not established. For some rows in the review, it is unclear which arms were selected and whether individual publications refer to the same participants.

A review of adults with various conditions, including cardiometabolic disorders, reported for waist circumference: SMD −0.081 (95% CI −0.224…+0.062). Study conditions and source limitations are considered separately.

Study findings. A review of adults with various conditions, including cardiometabolic disorders, reported for waist circumference: SMD −0.081 (95% CI −0.224…+0.062). Study conditions and source limitations are considered separately.

Studied regimen40–1500 mg/day, specific alternatives are given in the protocolsoral resveratrol preparations; in some trials the graph does not specify whether the single-ingredient or combination arm was selected
Duration and population12 weeks, 90 days, 3 months, 6 months, 8 weeks, 2 monthsHeterogeneous groups of adults; included conditions and groups: non-alcoholic fatty liver disease; metabolic syndrome; obesity; in some studies, no other diseases; type 2 diabetes; dyslipidemia; ulcerative colitis.

Comparison with control

Safety and limitations

The Canadian monograph advises consultation before use during pregnancy, breastfeeding, or when taking medicines or other products; gastrointestinal disturbances may occur at doses above 500 mg/day. The monograph applies to oral preparations for adults aged 18 and over and does not define regimens for children. In the skin study there were 11 mild adverse events, six led to withdrawal; events occurred in both active and control groups. In a 29-day study, 44 healthy volunteers received 0.5, 1, 2.5 or 5 g of resveratrol daily; 40 completed supplementation and four who withdrew were replaced. Gastrointestinal symptoms were reported at 2.5 and 5 g/day. The short study does not establish long-term safety. In a small study of 20 men with NAFLD, 3 g resveratrol daily for 8 weeks was associated with higher ALT and AST compared with placebo; the increase was observed through week 6. This is a signal of changes in liver enzymes, not an established diagnosis of liver injury.

RESVERATROL — Natural Health Product Monograph ↗ · Trans-resveratrol reduces visible signs of skin ageing in healthy adult females over 40: an 8-week randomized placebo-controlled trial ↗ · Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis ↗ · Resveratrol does not benefit patients with nonalcoholic fatty liver disease ↗

Interactions

WithEffectActionSource
CarbamazepineIn a study of 12 healthy volunteers, resveratrol 500 mg daily for 10 days increased the concentration and exposure of a single 200 mg dose of carbamazepine; clinical consequences and applicability to long-term use are not established.Before using them together, discuss the supplement with your treating physician or pharmacist; do not change your medication on your own.Effect of resveratrol on the pharmacokinetics of carbamazepine in healthy human volunteers ↗
RESVERATROL — Natural Health Product Monograph ↗
Anticoagulants and antiplatelet drugs, such as warfarin and clopidogrelResveratrol inhibited human platelet aggregation under laboratory conditions; an increased risk of bleeding when combined with these medicines is suspected, but the clinical frequency and magnitude of risk are not established.Consult a physician or pharmacist before using the supplement with these medicines.Resveratrol ↗
RESVERATROL — Natural Health Product Monograph ↗

Food sources

Foods contain free resveratrol and its derivatives, including piceid glycosides. Their content depends on the specific food; a food source differs in composition from capsules containing purified trans-resveratrol.

Resveratrol occurs in grapes, berries and peanuts; the amount depends on the food.

Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases ↗

Grapes and grape juice Resveratrol and its derivatives occur in grapes and grape juice; the skin is an important source in grapes. Content depends on variety and growing conditions.

Resveratrol ↗
Concentrations of resveratrol and derivatives in foods and estimation of dietary intake in a Spanish population: European Prospective Investigation into Cancer and Nutrition (EPIC)-Spain cohort ↗

Vaccinium berries Resveratrol was detected in tested samples of blueberries, bilberries, cranberries and lingonberries; content varied between samples.

Resveratrol, pterostilbene, and piceatannol in vaccinium berries ↗

Peanuts and peanut products Resveratrol was detected in peanuts; it also occurs in peanut butter. Amounts vary between varieties and products.

Occurrence of resveratrol in edible peanuts ↗
Resveratrol ↗

Cocoa and chocolate Cocoa and some products made from it contain resveratrol; composition and amount depend on the specific product.

Resveratrol ↗
Survey of the trans-resveratrol and trans-piceid content of cocoa-containing and chocolate products ↗

Studies

PublicationWhat was studiedParticipantsForm and doseResult
Sustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗randomized placebo-controlled trialPublications from one cohort: Sustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women (https://pmc.ncbi.nlm.nih.gov/articles/PMC7146200/); Long-term effects of resveratrol on cognition, cerebrovascular function and cardio-metabolic markers in postmenopausal women: A 24-month randomised, double-blind, placebo-controlled, crossover study (https://pubmed.ncbi.nlm.nih.gov/32900519/); Long-term resveratrol supplementation improves pain perception, menopausal symptoms, and overall well-being in postmenopausal women: findings from a 24-month randomized, controlled, crossover trial (https://pubmed.ncbi.nlm.nih.gov/32881835/). Overall mental task performance: Overall mental task performance Information processing speed: Information processing speed PCT picture comparison speed test: PCT picture comparison speed test TMT A sequential connecting-the-dots test: TMT A sequential connecting-the-dots test Language abilities: Language abilities PVT vocabulary test: PVT vocabulary test ORR oral reading recognition: ORR oral reading recognition Episodic memory: Episodic memory PSM picture sequence memory test: PSM picture sequence memory test Verbal memory: Verbal memory RAVLT immediate word recall: RAVLT immediate word recall RAVLT delayed word recall: RAVLT delayed word recall Working memory: Working memory LSWM working memory test: LSWM working memory test FSS spatial memory test: FSS spatial memory test Flexibility in switching between mental tasks: Flexibility in switching between mental tasks DCCS rule-switching test: DCCS rule-switching test FICA attention and inhibition test: FICA attention and inhibition test Sequential connecting of dots in the TMT: Sequential connecting of dots in the TMT Overall mental task performance: crossover comparison Composite pain score: Composite pain score Somatic symptoms: Somatic symptoms Overall well-being: Overall well-beingOverall mental task performance: Postmenopausal women; 146 randomized, 129 completed the first year Information processing speed: Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12 PCT picture comparison speed test: Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12 TMT A sequential connecting-the-dots test: Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12 Language abilities: Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12 PVT vocabulary test: Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12 ORR oral reading recognition: Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12 Episodic memory: Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12 PSM picture sequence memory test: Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12 Verbal memory: Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12 RAVLT immediate word recall: Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12 RAVLT delayed word recall: Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12 Working memory: Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12 LSWM working memory test: Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12 FSS spatial memory test: Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12 Flexibility in switching between mental tasks: Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12 DCCS rule-switching test: Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12 FICA attention and inhibition test: Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12 Sequential connecting of dots in the TMT: Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12 125 postmenopausal women in the RESHAW crossover study; the number analyzed for the individual outcome is not established Composite pain score: 125 postmenopausal women in the RESHAW crossover study; the number analyzed for the individual outcome is not established Somatic symptoms: 125 postmenopausal women in the RESHAW crossover study; the number analyzed for the individual outcome is not established Overall well-being: 125 postmenopausal women in the RESHAW crossover study; the number analyzed for the individual outcome is not establishedOverall mental task performance: synthetic trans-resveratrol >98%; 75 mg twice daily; 12 months; first phase of the crossover study; comparison: placebo Information processing speed: synthetic trans-resveratrol >98%; 75 mg twice daily; 12 months; first phase of the crossover study; comparison: placebo PCT picture comparison speed test: synthetic trans-resveratrol >98%; 75 mg twice daily; 12 months; first phase of the crossover study; comparison: placebo TMT A sequential connecting-the-dots test: synthetic trans-resveratrol >98%; 75 mg twice daily; 12 months; first phase of the crossover study; comparison: placebo Language abilities: synthetic trans-resveratrol >98%; 75 mg twice daily; 12 months; first phase of the crossover study; comparison: placebo PVT vocabulary test: synthetic trans-resveratrol >98%; 75 mg twice daily; 12 months; first phase of the crossover study; comparison: placebo ORR oral reading recognition: synthetic trans-resveratrol >98%; 75 mg twice daily; 12 months; first phase of the crossover study; comparison: placebo Episodic memory: synthetic trans-resveratrol >98%; 75 mg twice daily; 12 months; first phase of the crossover study; comparison: placebo PSM picture sequence memory test: synthetic trans-resveratrol >98%; 75 mg twice daily; 12 months; first phase of the crossover study; comparison: placebo Verbal memory: synthetic trans-resveratrol >98%; 75 mg twice daily; 12 months; first phase of the crossover study; comparison: placebo RAVLT immediate word recall: synthetic trans-resveratrol >98%; 75 mg twice daily; 12 months; first phase of the crossover study; comparison: placebo RAVLT delayed word recall: synthetic trans-resveratrol >98%; 75 mg twice daily; 12 months; first phase of the crossover study; comparison: placebo Working memory: synthetic trans-resveratrol >98%; 75 mg twice daily; 12 months; first phase of the crossover study; comparison: placebo LSWM working memory test: synthetic trans-resveratrol >98%; 75 mg twice daily; 12 months; first phase of the crossover study; comparison: placebo FSS spatial memory test: synthetic trans-resveratrol >98%; 75 mg twice daily; 12 months; first phase of the crossover study; comparison: placebo Flexibility in switching between mental tasks: synthetic trans-resveratrol >98%; 75 mg twice daily; 12 months; first phase of the crossover study; comparison: placebo DCCS rule-switching test: synthetic trans-resveratrol >98%; 75 mg twice daily; 12 months; first phase of the crossover study; comparison: placebo FICA attention and inhibition test: synthetic trans-resveratrol >98%; 75 mg twice daily; 12 months; first phase of the crossover study; comparison: placebo Sequential connecting of dots in the TMT: synthetic trans-resveratrol >98%; 75 mg twice daily; 12 months; first phase of the crossover study; comparison: placebo trans-resveratrol; 75 mg twice daily; 12 months per period, 24 months total; comparison: placebo; crossover comparison Composite pain score: trans-resveratrol; 75 mg twice daily; 12 months per period; comparison: placebo Somatic symptoms: trans-resveratrol; 75 mg twice daily; 12 months per period, 24 months total; comparison: placebo; crossover comparison Overall well-being: trans-resveratrol; 75 mg twice daily; 12 months per period, 24 months total; comparison: placebo; crossover comparisonOverall mental task performance: In postmenopausal women in the RESHAW study, the authors reported a small effect on the overall cognitive score after 12 months of supplementation; group values and the authors’ between-group estimate are presented separately. Information processing speed: In the study of postmenopausal women, the information processing speed measure after 12 months: At baseline −0.08 ± 0.10 versus 0.05 ± 0.09, at 12 months 0.24 ± 0.09 versus 0.23 ± 0.10; z-scores, mean ± SEM; values as in the table. The authors reported a statistically significant between-group difference in change. PCT picture comparison speed test: In the study of postmenopausal women, the PCT picture comparison speed test measure after 12 months: At baseline −0.13 ± 0.13 versus 0.08 ± 0.12, at 12 months 0.32 ± 0.11 versus 0.15 ± 0.13; z-scores, mean ± SEM; values as in the table. The authors reported a statistically significant between-group difference in change. TMT A sequential connecting-the-dots test: In the study of postmenopausal women, the TMT A sequential connecting-the-dots test measure after 12 months: At baseline −0.02 ± 0.11 versus 0.02 ± 0.13, at 12 months 0.16 ± 0.11 versus 0.31 ± 0.11; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change. Language abilities: In the study of postmenopausal women, the language abilities measure after 12 months: At baseline 0.03 ± 0.11 versus −0.03 ± 0.10, at 12 months 0.09 ± 0.11 versus 0.04 ± 0.11; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change. PVT vocabulary test: In the study of postmenopausal women, the PVT vocabulary test measure after 12 months: At baseline 0.09 ± 0.12 versus −0.09 ± 0.12, at 12 months 0.20 ± 0.13 versus 0.05 ± 0.13; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change. ORR oral reading recognition: In the study of postmenopausal women, the ORR oral reading recognition measure after 12 months: At baseline −0.02 ± 0.12 versus 0.02 ± 0.12, at 12 months −0.02 ± 0.11 versus 0.04 ± 0.10; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change. Episodic memory: In the study of postmenopausal women, the episodic memory measure after 12 months: At baseline −0.47 ± 0.10 versus −0.49 ± 0.09, at 12 months −0.19 ± 0.11 versus −0.27 ± 0.10; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change. PSM picture sequence memory test: In the study of postmenopausal women, the PSM picture sequence memory test measure after 12 months: At baseline −0.47 ± 0.10 versus −0.49 ± 0.09, at 12 months −0.19 ± 0.11 versus −0.27 ± 0.10; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change. Verbal memory: In the study of postmenopausal women, the verbal memory measure after 12 months: At baseline −0.001 ± 0.1 versus 0.001 ± 0.1, at 12 months 0.12 ± 0.10 versus 0.17 ± 0.12; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change. RAVLT immediate word recall: In the study of postmenopausal women, the RAVLT immediate word recall measure after 12 months: At baseline −0.02 ± 0.07 versus 0.02 ± 0.07, at 12 months 0.07 ± 0.06 versus 0.07 ± 0.06; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change. RAVLT delayed word recall: In the study of postmenopausal women, the RAVLT delayed word recall measure after 12 months: At baseline 0.02 ± 0.15 versus −0.02 ± 0.15, at 12 months 0.17 ± 0.16 versus 0.28 ± 0.19; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change. Working memory: In the study of postmenopausal women, the working memory measure after 12 months: At baseline −0.04 ± 0.10 versus 0.04 ± 0.10, at 12 months 0.05 ± 0.09 versus 0.06 ± 0.09; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change. LSWM working memory test: In the study of postmenopausal women, the LSWM working memory test measure after 12 months: At baseline −0.11 ± 0.12 versus 0.11 ± 0.11, at 12 months −0.03 ± 0.13 versus 0.08 ± 0.14; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change. FSS spatial memory test: In the study of postmenopausal women, the FSS spatial memory test measure after 12 months: At baseline 0.04 ± 0.11 versus −0.04 ± 0.12, at 12 months 0.12 ± 0.10 versus 0.06 ± 0.12; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change. Flexibility in switching between mental tasks: In the study of postmenopausal women, the cognitive flexibility measure after 12 months: At baseline 0.03 ± 0.08 versus −0.03 ± 0.12, at 12 months 0.82 ± 0.07 versus 0.78 ± 0.08; z-scores, mean ± SEM; values as in the table. The authors reported a statistically significant between-group difference in change. DCCS rule-switching test: In the study of postmenopausal women, the DCCS rule-switching test measure after 12 months: At baseline 0.05 ± 0.09 versus −0.05 ± 0.14, at 12 months 0.23 ± 0.10 versus 0.10 ± 0.13; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change. FICA attention and inhibition test: In the study of postmenopausal women, the FICA attention and inhibition test measure after 12 months: At baseline 0.08 ± 0.11 versus −0.08 ± 0.12, at 12 months 0.26 ± 0.12 versus 0.22 ± 0.11; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change. Sequential connecting of dots in the TMT: In the study of postmenopausal women, the TMT test score measure after 12 months: At baseline −0.02 ± 0.19 versus 0.02 ± 0.21, at 12 months 1.97 ± 0.11 versus 2.01 ± 0.10; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change. In the RESHAW crossover study of postmenopausal women, for the overall cognitive score: Cohen d=0.170, p=0.005; the authors reported a 33% relative change in the composite score. Composite pain score: In the RESHAW crossover study of postmenopausal women, for the composite pain score: the authors reported improvement in the composite pain score, p<0.001; a quantitative between-group difference was not provided in the available abstract. Somatic symptoms: In the RESHAW crossover study of postmenopausal women, for somatic symptoms: the authors reported improvement in somatic symptoms, p=0.024; a quantitative difference was not provided in the abstract. Overall well-being: In the RESHAW crossover study of postmenopausal women, for overall well-being: the authors reported improvement in overall well-being, p=0.010; a quantitative difference was not provided in the abstract.
Trans-resveratrol reduces visible signs of skin ageing in healthy adult females over 40: an 8-week randomized placebo-controlled trial ↗randomized placebo-controlled trialWrinkles: capsulesHealthy women aged 40 and over; 61 participants in the comparison: 32 in the oral group and 29 in the double-placebo grouptrans-resveratrol capsules; 75 mg twice daily plus placebo cream; 8 weeks; comparison: double placeboIn an eight-week study of healthy women aged 40 and over, between-group significance of the change in the total wrinkle score was not indicated in the table for the oral resveratrol-only group.

Sources

Sources
  1. Sustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗
  2. Trans-resveratrol reduces visible signs of skin ageing in healthy adult females over 40: an 8-week randomized placebo-controlled trial ↗
  3. Resveratrol blunts the positive effects of exercise training on cardiovascular health in aged men ↗
  4. Effects of Resveratrol Supplementation on Delayed Onset Muscle Soreness and Muscle Recovery: A Systematic Review ↗
  5. Long-term effects of resveratrol on cognition, cerebrovascular function and cardio-metabolic markers in postmenopausal women: A 24-month randomised, double-blind, placebo-controlled, crossover study ↗
  6. Long-term resveratrol supplementation improves pain perception, menopausal symptoms, and overall well-being in postmenopausal women: findings from a 24-month randomized, controlled, crossover trial ↗
  7. Effects of resveratrol on postmenopausal women: a systematic review and meta-analysis ↗
  8. RESVERATROL — Natural Health Product Monograph ↗
  9. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis ↗
  10. Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases ↗
  11. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis ↗
  12. Resveratrol does not benefit patients with nonalcoholic fatty liver disease ↗
  13. Effect of resveratrol on the pharmacokinetics of carbamazepine in healthy human volunteers ↗
  14. Resveratrol ↗
  15. Occurrence of resveratrol in edible peanuts ↗
  16. Resveratrol, pterostilbene, and piceatannol in vaccinium berries ↗
  17. Concentrations of resveratrol and derivatives in foods and estimation of dietary intake in a Spanish population: European Prospective Investigation into Cancer and Nutrition (EPIC)-Spain cohort ↗
  18. Survey of the trans-resveratrol and trans-piceid content of cocoa-containing and chocolate products ↗